Zinab O. Doha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zinab O. Doha has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Rosalie C. Sears
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA
28 shared publications - Ellen M. Langer
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR
26 shared publications - Jennifer Eng
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR
26 shared publications - Koei Chin
Oregon Health & Science University 3 Knight Cancer Institute Portland, Oregon
26 shared publications - Aaron Reid Doe
Oregon Health and Science University
25 shared publications - Amy S. Farrell
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon
25 shared publications
Latest Publications
- Open Access
Integrative Molecular Profiling and Single-Cell Characterization of LHFPL5 Reveal Cancer-Specific Regulatory Features in Clear Cell Renal Cell Carcinoma and Lung Adenocarcinoma
Background and Objectives: LHFPL5 encodes a four-pass transmembrane protein essential for cochlear mechanotransduction, but its molecular behavior in cancer remains poorly defined. We characterized the genomic, epigenetic, transcriptomic, immune, and cellular context of LHFPL5 in clear cell renal cell carcinoma (KIRC) and lung adenocarcinoma (LUAD), along with its associations with clinical outcomes. Materials and Methods: Retrospective analyses integrated TCGA RNA sequencing, clinical, DNA methylation, copy number, tumor purity, and immune deconvolution data. Transcriptome-wide associations and Hallmark enrichment defined LHFPL5-associated programs. Continuous-expression Cox models estimated hazard ratios (HRs) per standard-deviation increase, adjusted for age, sex, and pathological stage. GEO cohorts assessed external reproducibility, matched TCGA expression pipelines assessed processing sensitivity, and three non-TCGA single-cell datasets examined cellular localization. Results: LHFPL5 showed distinct molecular contexts in KIRC and LUAD. In KIRC, higher expression remained associated with poorer overall survival after clinical adjustment (528 patients; 174 deaths; HR = 1.36, 95% CI 1.21–1.53; p = 2.42 × 10−7), while subtype and immune fractions showed limited statistical overlap with the association. In LUAD, expression covaried with copy-number state and showed a weak inverse relationship with first-exon methylation. Proliferation-related transcriptional programs were associated with survival, although enrichment support depended on the multiple-testing procedure. The primary STAR-derived LUAD analysis was null (485 patients; 177 deaths; HR = 1.02, 95% CI 0.89–1.18; p = 0.770), and survival inference varied with RNA processing. External adjusted replication was inconclusive. Single-cell detection was sparse in KIRC and one LUAD dataset; another LUAD cohort showed more frequent epithelial detection without resolved malignant-cell identity. Conclusions: LHFPL5 exhibits cancer-specific molecular architecture. LUAD showed copy-number, methylation, and proliferation-related associations, whereas KIRC showed a distinct molecular context with an independent survival signal. These findings support context-dependent LHFPL5 regulation and prioritize genomic, epigenetic, and transcriptional mechanisms for functional investigation.
Open AccessIntegrative Molecular Profiling and Single-Cell Characterization of LHFPL5 Reveal Cancer-Specific Regulatory Features in Clear Cell Renal Cell Carcinoma and Lung Adenocarcinoma
Background and Objectives: LHFPL5 encodes a four-pass transmembrane protein essential for cochlear mechanotransduction, but its molecular behavior in cancer remains poorly defined. We characterized the genomic, epigenetic, transcriptomic, immune, and cellular context of LHFPL5 in clear cell renal cell carcinoma (KIRC) and lung adenocarcinoma (LUAD), along with its associations with clinical outcomes. Materials and Methods: Retrospective analyses integrated TCGA RNA sequencing, clinical, DNA methylation, copy number, tumor purity, and immune deconvolution data. Transcriptome-wide associations and Hallmark enrichment defined LHFPL5-associated programs. Continuous-expression Cox models estimated hazard ratios (HRs) per standard-deviation increase, adjusted for age, sex, and pathological stage. GEO cohorts assessed external reproducibility, matched TCGA expression pipelines assessed processing sensitivity, and three non-TCGA single-cell datasets examined cellular localization. Results: LHFPL5 showed distinct molecular contexts in KIRC and LUAD. In KIRC, higher expression remained associated with poorer overall survival after clinical adjustment (528 patients; 174 deaths; HR = 1.36, 95% CI 1.21–1.53; p = 2.42 × 10−7), while subtype and immune fractions showed limited statistical overlap with the association. In LUAD, expression covaried with copy-number state and showed a weak inverse relationship with first-exon methylation. Proliferation-related transcriptional programs were associated with survival, although enrichment support depended on the multiple-testing procedure. The primary STAR-derived LUAD analysis was null (485 patients; 177 deaths; HR = 1.02, 95% CI 0.89–1.18; p = 0.770), and survival inference varied with RNA processing. External adjusted replication was inconclusive. Single-cell detection was sparse in KIRC and one LUAD dataset; another LUAD cohort showed more frequent epithelial detection without resolved malignant-cell identity. Conclusions: LHFPL5 exhibits cancer-specific molecular architecture. LUAD showed copy-number, methylation, and proliferation-related associations, whereas KIRC showed a distinct molecular context with an independent survival signal. These findings support context-dependent LHFPL5 regulation and prioritize genomic, epigenetic, and transcriptional mechanisms for functional investigation.
- Open Access
- 20 August 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (8) , 846
Tumor-Intrinsic DNA Damage Signaling Is Associated with MHC-I Expression and CD8 Cytotoxic T-Cell Engagement in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is characterized by marked immune microenvironment heterogeneity and variable chemotherapy response, yet the epithelial transcriptional programs governing cytotoxic immune activation remain poorly understood. We performed an exploratory, integrative analysis using single-cell RNA sequencing of 31,962 cells from eight TNBC patients operationally stratified into Good and Bad Prognosis groups based on pathological lymphoid infiltration, a discovery grouping subsequently validated against pathological complete response (pCR) in three independent bulk RNA-seq cohorts. This analysis identified four epithelial transcriptional states. The G5 DNA damage subpopulation—predominantly restricted to Good Prognosis tumors (29.2% vs. 0%)—and the G4 Metabolism subpopulation—2.4-fold enriched in Bad Prognosis—were the primary prognostic signatures. Machine learning validation using nested leave-one-cohort-out (LOCO) cross-validation across 614 samples demonstrated that G4 + G5 raw genes with random forest yielded the largest observed mean AUC of 0.653, though these results are exploratory and do not establish a validated clinical classifier. CellChat ligand–receptor interaction analysis revealed that G5 DNA-damage epithelial cells are the dominant immune activators in Good Prognosis TNBC, predominantly engaging CD8 cytotoxic T cells through MHC-I antigen presentation via HLA-A/B/C/E/F → CD8A/CD8B interactions, the highest-probability signaling pathway identified. Spatial transcriptomics independently validated significantly higher DNA damage and CD8 T-cell scores in Good Prognosis tissue. Together, these exploratory findings suggest a framework in which tumor-intrinsic DNA damage signaling is associated with MHC-I antigen presentation upregulation and CD8 cytotoxic T-cell engagement, supporting further investigation of this axis and its potential implications for combining DNA-damaging chemotherapy with immune checkpoint blockade in TNBC.
- 20 August 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (8) , 846
Open AccessTumor-Intrinsic DNA Damage Signaling Is Associated with MHC-I Expression and CD8 Cytotoxic T-Cell Engagement in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is characterized by marked immune microenvironment heterogeneity and variable chemotherapy response, yet the epithelial transcriptional programs governing cytotoxic immune activation remain poorly understood. We performed an exploratory, integrative analysis using single-cell RNA sequencing of 31,962 cells from eight TNBC patients operationally stratified into Good and Bad Prognosis groups based on pathological lymphoid infiltration, a discovery grouping subsequently validated against pathological complete response (pCR) in three independent bulk RNA-seq cohorts. This analysis identified four epithelial transcriptional states. The G5 DNA damage subpopulation—predominantly restricted to Good Prognosis tumors (29.2% vs. 0%)—and the G4 Metabolism subpopulation—2.4-fold enriched in Bad Prognosis—were the primary prognostic signatures. Machine learning validation using nested leave-one-cohort-out (LOCO) cross-validation across 614 samples demonstrated that G4 + G5 raw genes with random forest yielded the largest observed mean AUC of 0.653, though these results are exploratory and do not establish a validated clinical classifier. CellChat ligand–receptor interaction analysis revealed that G5 DNA-damage epithelial cells are the dominant immune activators in Good Prognosis TNBC, predominantly engaging CD8 cytotoxic T cells through MHC-I antigen presentation via HLA-A/B/C/E/F → CD8A/CD8B interactions, the highest-probability signaling pathway identified. Spatial transcriptomics independently validated significantly higher DNA damage and CD8 T-cell scores in Good Prognosis tissue. Together, these exploratory findings suggest a framework in which tumor-intrinsic DNA damage signaling is associated with MHC-I antigen presentation upregulation and CD8 cytotoxic T-cell engagement, supporting further investigation of this axis and its potential implications for combining DNA-damaging chemotherapy with immune checkpoint blockade in TNBC.
- Open Access
- 9 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6157
Integrative Single-Cell and Bulk Transcriptomic Analyses with Spatial Validation Identify a Residual Fatty Acid–EMT Subset Driving Chemotherapy Resistance in Triple-Negative Breast Cancer via MIF- and MK-Mediated Ligand–Receptor Signaling
Chemotherapy resistance in triple-negative breast cancer (TNBC) remains a critical clinical challenge, with a substantial proportion of patients failing to achieve pathological complete response following neoadjuvant chemotherapy (NAC). Using an integrative single-cell RNA sequencing (scRNA-seq), bulk transcriptomic, and spatial proteomic framework, we aimed to identify the malignant epithelial subset driving this resistance and the intercellular signaling axes through which it reprograms the tumor microenvironment (TME). scRNA-seq analysis of NAC-treated breast tumors revealed a Fatty Acid–EMT co-expressing epithelial subset (FA-EMT) that is selectively enriched in the chemotherapy-resistant residuum. Critically, FA-EMT co-expression—rather than either program individually—most powerfully predicted chemotherapy resistance and reduced overall survival across two independent bulk transcriptomic cohorts comprising 277 TNBC patients (p < 0.001). CellChat ligand–receptor analysis established FA-EMT cells as the dominant TME signaling hub, deploying MDK–NCL and MIF–CD74–CXCR4 axes to simultaneously suppress adaptive and innate anti-tumor immunity via T-cell exhaustion, Treg activation, and the expansion of myeloid-derived suppressor cells. Spatial CyCIF validation in a published paclitaxel-resistant TNBC mouse model (n = 69 cores) confirmed significant Metabolic-EMT enrichment in resistant tumor cores (p = 0.0085) with physical co-localization with immunosuppressive MDSC and Treg populations. These findings establish the FA-EMT subset as a key cellular driver of treatment failure in TNBC and nominate MDK–NCL and MIF–CD74–CXCR4 as mechanistically grounded therapeutic targets with the potential to dismantle the FA-EMT-driven immunosuppressive niche and sensitize chemotherapy-resistant TNBC to cytotoxic treatment.
- 9 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6157
Open AccessIntegrative Single-Cell and Bulk Transcriptomic Analyses with Spatial Validation Identify a Residual Fatty Acid–EMT Subset Driving Chemotherapy Resistance in Triple-Negative Breast Cancer via MIF- and MK-Mediated Ligand–Receptor Signaling
Chemotherapy resistance in triple-negative breast cancer (TNBC) remains a critical clinical challenge, with a substantial proportion of patients failing to achieve pathological complete response following neoadjuvant chemotherapy (NAC). Using an integrative single-cell RNA sequencing (scRNA-seq), bulk transcriptomic, and spatial proteomic framework, we aimed to identify the malignant epithelial subset driving this resistance and the intercellular signaling axes through which it reprograms the tumor microenvironment (TME). scRNA-seq analysis of NAC-treated breast tumors revealed a Fatty Acid–EMT co-expressing epithelial subset (FA-EMT) that is selectively enriched in the chemotherapy-resistant residuum. Critically, FA-EMT co-expression—rather than either program individually—most powerfully predicted chemotherapy resistance and reduced overall survival across two independent bulk transcriptomic cohorts comprising 277 TNBC patients (p < 0.001). CellChat ligand–receptor analysis established FA-EMT cells as the dominant TME signaling hub, deploying MDK–NCL and MIF–CD74–CXCR4 axes to simultaneously suppress adaptive and innate anti-tumor immunity via T-cell exhaustion, Treg activation, and the expansion of myeloid-derived suppressor cells. Spatial CyCIF validation in a published paclitaxel-resistant TNBC mouse model (n = 69 cores) confirmed significant Metabolic-EMT enrichment in resistant tumor cores (p = 0.0085) with physical co-localization with immunosuppressive MDSC and Treg populations. These findings establish the FA-EMT subset as a key cellular driver of treatment failure in TNBC and nominate MDK–NCL and MIF–CD74–CXCR4 as mechanistically grounded therapeutic targets with the potential to dismantle the FA-EMT-driven immunosuppressive niche and sensitize chemotherapy-resistant TNBC to cytotoxic treatment.
- Open Access
Multi-Modal Profiling Reveals SERPINB3-Driven Immune Evasion and Stromal Immune Mimicry in Triple-Negative Breast Cancer
Background/Objectives: Triple-negative breast cancer (TNBC) exhibits high immune infiltration yet remains clinically aggressive. Although immune checkpoint blockade benefits a subset of patients, the molecular programs enabling concurrent immune activation and immune evasion in TNBC are not fully defined. This study aimed to identify TNBC-specific tumor-intrinsic and tumor-extrinsic molecular features that may explain this paradox. Methods: Publicly available single-cell RNA-sequencing data from primary breast tumors were analyzed to characterize subtype-specific transcriptional programs across epithelial and stromal compartments. Tumor-intrinsic findings were independently validated using bulk transcriptomic and clinical data from the METABRIC cohort. Tumor microenvironment remodeling was evaluated using multiplexed tissue imaging of TNBC tumors. Functional analyses were done included Gene Ontology enrichment, Hallmark gene set enrichment analysis, and SERPINB3-centered protein–protein interaction network analysis using STRING. Results: Single-cell analysis identified SERPINB3 as a TNBC-enriched epithelial gene relative to ER+ and HER2+ tumors. This subtype-restricted pattern was validated in the METABRIC cohort and associated with pathways related to epithelial–mesenchymal transition, interferon signaling, and antigen presentation. TNBC tumors also displayed a humoral immune signature characterized by B-cell and plasmablast enrichment, as well as ectopic immunoglobulin gene expression in cancer-associated fibroblasts, endothelial cells, and myeloid populations. Multiplex imaging revealed coordinated associations between immune suppression, stromal activation, and tumor proliferation. Network analysis placed SERPINB3 within interconnected immune-regulatory and stromal signaling modules. Conclusions: Together, these data indicate that TNBC exhibits co-existing immune activation and immune-suppressive features. The identified epithelial and stromal signatures represent candidate biomarkers that may inform future studies of immune regulation and therapeutic stratification in TNBC.
Open AccessMulti-Modal Profiling Reveals SERPINB3-Driven Immune Evasion and Stromal Immune Mimicry in Triple-Negative Breast Cancer
Background/Objectives: Triple-negative breast cancer (TNBC) exhibits high immune infiltration yet remains clinically aggressive. Although immune checkpoint blockade benefits a subset of patients, the molecular programs enabling concurrent immune activation and immune evasion in TNBC are not fully defined. This study aimed to identify TNBC-specific tumor-intrinsic and tumor-extrinsic molecular features that may explain this paradox. Methods: Publicly available single-cell RNA-sequencing data from primary breast tumors were analyzed to characterize subtype-specific transcriptional programs across epithelial and stromal compartments. Tumor-intrinsic findings were independently validated using bulk transcriptomic and clinical data from the METABRIC cohort. Tumor microenvironment remodeling was evaluated using multiplexed tissue imaging of TNBC tumors. Functional analyses were done included Gene Ontology enrichment, Hallmark gene set enrichment analysis, and SERPINB3-centered protein–protein interaction network analysis using STRING. Results: Single-cell analysis identified SERPINB3 as a TNBC-enriched epithelial gene relative to ER+ and HER2+ tumors. This subtype-restricted pattern was validated in the METABRIC cohort and associated with pathways related to epithelial–mesenchymal transition, interferon signaling, and antigen presentation. TNBC tumors also displayed a humoral immune signature characterized by B-cell and plasmablast enrichment, as well as ectopic immunoglobulin gene expression in cancer-associated fibroblasts, endothelial cells, and myeloid populations. Multiplex imaging revealed coordinated associations between immune suppression, stromal activation, and tumor proliferation. Network analysis placed SERPINB3 within interconnected immune-regulatory and stromal signaling modules. Conclusions: Together, these data indicate that TNBC exhibits co-existing immune activation and immune-suppressive features. The identified epithelial and stromal signatures represent candidate biomarkers that may inform future studies of immune regulation and therapeutic stratification in TNBC.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Dataset 6 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
DESeq2 comparing DMSO untreated vs TGFβ treated
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Dataset 6 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
DESeq2 comparing DMSO untreated vs TGFβ treated
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
PIN1 loss impacts KPC pancreas weight and fibroblast ⍺SMA expression
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
PIN1 loss impacts KPC pancreas weight and fibroblast ⍺SMA expression
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Dataset 2 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
DESeq2 for shSCR PSCs comparing TGF-β treated vs untreated
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Dataset 2 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
DESeq2 for shSCR PSCs comparing TGF-β treated vs untreated
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Dataset 4 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
CAF marker FPKMs in knockdown samples
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Dataset 4 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
CAF marker FPKMs in knockdown samples
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Dataset 11 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
Secreted Signals overlap with DEGs (FPKMs)
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Dataset 11 from The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
Secreted Signals overlap with DEGs (FPKMs)